Motion DNA Seeks Major Agreement With Pro Sports League; League Could Be First to Implement Mandatory Testing of Athletes

Main Category: Sports Medicine / Fitness
Article Date: 18 Apr 2005 - 0:00 PDT


Motion DNA Corporation (OTC: MTDX) officials announced today the company has entered negotiations with the National Pro FastPitch League. If approved, the league would become the first professional organization to endorse and support biomechanics testing of all athletes. Motion DNA would become the official biomechanical analysis company of the second year women's pro sports league. Under the agreement, Motion DNA would conduct at least one annual analysis on each member of the NPF's six teams, assisting in the overall development of each individual player and success of the league.

"The popularity of women's softball is at an all-time high," said Zig Ziegler, president of Motion DNA. "We believe this league will be successful quickly with the presence of more than half of the 2004 US Olympic Gold medalists in softball representing teams in the league, including Jennie Finch, Lovie Jung, Natasha Whatley and Crystal Bustos, all former top collegiate all-Americans as well."

Currently, more than six million youth girls, ages six to eighteen play softball in competitive and recreational programs in the United States alone.

"The NPF gives those girls a new target and can help increase the popularity of the sport as salaries of players increase and more playing opportunities evolve," said Lauren Bay, a member of the Canadian Olympic team, currently enrolled in a Motion DNA program and member of the NPF's Chicago Bandits.

Motion DNA expects a deal to be reached quickly, with the season scheduled to begin in late May. "We already have several NPF athletes training at our Scottsdale lab, benefiting from weekly analyses," added Ziegler. "Once we are able to kick off this relationship, we expect to see an increase in our college and youth sports team client base as more athletes pursue an edge over their competition."

Motion DNA Corporation provides diagnostic testing for medical professionals and sports organizations. Motion DNA's biomechanical analyses and detailed reports provide its customers and consumers with solutions for preventing injuries, identifying physical limitations, diagnosing pre-existing injuries related to biomechanics, and improving physical performance levels.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors. The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.

For more information on Motion DNA Contact:
Investor Relations
Motion DNA Corporation
15023 N. 73rd Street
Scottsdale, Arizona 85260
1.877.425.7734 toll free
480.425.7734 phone
480.991.7736 fax
http://www.motiondnacorp.com/home.htm

• Additional
• References
• Citations